|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01276 HENGRUI PHARMA
Nominal 
49.660 -5.290 (-9.627%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 15,455,584 | -1.939% | 31,629,416 | 27,984,605 | 22,819,785 | 21,275,271 |
| Cost of Sales | (2,113,343) | -0.077% | (4,362,656) | (3,848,177) | (3,525,248) | (3,486,639) |
| Gross Profit | 13,342,241 | -2.228% | 27,266,760 | 24,136,428 | 19,294,537 | 17,788,632 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (72,123) | 73.929% | (97,143) | (21,581) | (72,696) | (62,996) | |
| Profit / (Loss) before Taxation | 4,952,417 | -1.950% | 8,707,625 | 7,169,690 | 4,667,110 | 3,968,492 | |
| Taxation | (487,135) | -18.302% | (990,623) | (832,695) | (389,289) | (153,351) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 157 | -- | (5,947) | (468) | 24,615 | 91,233 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,465,439 | 0.345% | 7,711,055 | 6,336,527 | 4,302,436 | 3,906,374 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (698,327) | 187.466% | (771,038) | (597,718) | (471,238) | (378,784) |
| Depreciation & Amortisation | 535,514 | 15.964% | 942,470 | 870,819 | 793,937 | 640,511 |
| Directors' Emoluments | -- | -- | 37,824 | 25,945 | 20,418 | 10,537 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 68.000 | -2.857% | 119.000 | 100.000 | 68.000 | 61.000 |
| DPS (cts) | 0.000 | -- | 20.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | 16.807% | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.728 | 1.169 | 1.202 | 0.198 |
| NBV per share ($) | 9.713 | -- | 9.237 | -- | -- | -- |
| Remarks: | Real time quote last updated: 20/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,465,439 |
| %Change | 0.345% |
| EPS / (LPS) | RMB 0.680 |
| NBV Per Share (¥) | RMB 9.713 |